Showing 1 - 12 results of 12 for search '"ПОЛИМОРФНАЯ ЖЕЛУДОЧКОВАЯ ТАХИКАРДИЯ"', query time: 0.56s Refine Results
  1. 1
    Academic Journal

    Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 1 (2025); 42-49 ; Российский вестник перинатологии и педиатрии; Том 70, № 1 (2025); 42-49 ; 2500-2228 ; 1027-4065

    File Description: application/pdf

    Relation: https://www.ped-perinatology.ru/jour/article/view/2138/1565; Roston T.M., Yuchi Z., Kannankeril P.J., Hathaway J., Vinocur J.M., Etheridge S.P., et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace 2018; 20(3): 541–547. DOI:10.1093/europace/euw389; Josephs K., Patel K., Janson C.M., Montagna C., McDonald V.T. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2017; 5(6): 788–794. DOI:10.1002/mgg3.323; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях. Альманах клинической медицины 2023; 51(3): 192–199. DOI 10.18786/2072–0505–2023–51–022; Webster G., Aburawi E.H., Chaix M.A., Chandler S., Foo R., Monwarul Islam A.K.M., et al. Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace 2021; 23(5): 781–788. DOI:10.1093/europace/euaa376; Wang G., Zhao N., Zhong S., Wang Y., Li J. Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. Medicine 2019; 98(34): p e16961. DOI:10.1097/MD.0000000000016961; Galimberti E.S., Knollmann B.C. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011; 51(5): 760–768. DOI:10.1016/j.yjmcc.2011.07.002; Marx A., Lange B., Nalenz C., Hoffmann B., Rostock T., Konrad T. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports 2019; 5(2): 74–77. DOI:10.1016/j.hrcr.2018.04.003; Li S., Lv T., Yang J., Li K., Yang Y., Zhang P. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol 2023; 50 (1): 39–49. DOI:10.1111/1440–1681.13722; Veith M., El-Battrawy I., Roterberg G., Raschwitz L., Lang S., Wolpert C., et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020; 9(4): 123–131. DOI:10.3390/jcm9040903; Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A., et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J, 2022. 43(40): p. 3997–4126. DOI:10.1161/CIR.0000000000000548; Duan H., Lu Y., Yan S., Qiao L., Hua Y., Li Y., et al. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Medicine (Baltimore) 2018; 97(16): 63–68. DOI:10.1097/MD.0000000000010368; Friday K.P., Moak J.P., Fries M.H., Iqbal S.N. Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible? Pediatric Cardiology 2015; 36(7): 1542–1547. DOI:10.1007/s00246–015–1232–3; Hwang H.S., Hasdemir C., Laver D., Mehra D., Turhan K., Faggioni M., et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class i antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology 2011; 4(2): 128–135. DOI:10.1161/CIRCEP.110.959916; Lawrenz W., Krogmann O.N., Wieczorek M. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene. Cardiol Young 2014; 24 (4): 741–744. DOI:10.1017/S1047951113001091; Kulbachinskaya E., Bereznitskaya V. Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study. Annals of Pediatric Cardiology 2024; 17 (3): 196–203. DOI:10.4103/apc.apc_101_24

  2. 2
  3. 3
  4. 4
    Academic Journal

    Contributors: 1

    Source: Almanac of Clinical Medicine; Vol 51, No 3 (2023); 192-199 ; Альманах клинической медицины; Vol 51, No 3 (2023); 192-199 ; 2587-9294 ; 2072-0505

    File Description: application/pdf

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12